medigraphic.com
ISSN 0188-2198 (Impreso)

2011, Número 1

<< Anterior Siguiente >>

Rev Mex Cardiol 2011; 22 (1)


Prótesis endovasculares medicadas contra de metal en la angioplastia primaria, reporte de un centro hospitalario en México

Baena SE, Palacios RJM, Jiménez TO, Ficker LGB, Galván GE, Díaz DLGE, Acuña MVH, Fong PM

Idioma: Español
Referencias bibliográficas: 37
Paginas: 24-30
Archivo PDF: 215.96 Kb.


RESUMEN

El objetivo del estudio es comparar los resultados clínicos a 30 días en el tratamiento de infarto agudo del miocardio (IAM) con elevación del ST en pacientes tratados con prótesis endovasculares medicadas contra de metal en un hospital de cardiología de México. Resultados: De febrero de 1996 a marzo del 2008 se realizaron 800 angioplastias primarias; en 433 pacientes (54%) se les colocó algún tipo de prótesis endovascular, en el resto sólo balón de angioplastia coronaria. La muerte a los 30 días fue de 4.9% en los pacientes con IAM y colocación de prótesis medicadas y del 4.2% en los pacientes con colocación de prótesis de metal (p NS), el reinfarto se observó en 0 y 3%, la trombosis protésica en 4.9 y 1.1%, la isquemia residual en 4.9 y 5%, la necesidad de cirugía de revascularización en 0 y 0.8%, los sangrados mayores en 0 y 1.9% respectivamente y no se describen eventos vasculares cerebrales agudos (todas con p NS). Conclusiones: A 30 días del IAM en los puntos finales de muerte y eventos cardiovasculares mayores no se encontró diferencia estadística significativa entre la colocación de prótesis medicadas contra de metal. El éxito del procedimiento es elevado (88%) y las complicaciones bajas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. http://www.inegi.gob.mx/est/contenidos/espanol/rutinas/ept.asp?t=mpob45&s=est&c=3222.

  2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13-20.

  3. Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093-2098.

  4. Kastrati A, Mehilli J, Dirschinger J et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomized trial. Lancet 2002; 359: 920-925.

  5. Stone GW, Brodie BR, Griffin JJ et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary angioplasty in myocardial infarction stent pilot trial investigators. J Am Coll Cardiol 1998; 31: 23-30.

  6. Grines CL, Cox DA, Stone GW et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent primary angioplasty in myocardial infarction study group. N Engl J Med 1999; 341: 1949-1956.

  7. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297-301.

  8. Sidney CS Jr, Chair TEF, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O’Neill WW, Schaff HV, Whitlow PL, Williams DO. ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI 2005 Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-e286.

  9. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1886-1889.

  10. Pittl U, Kaiser C, Brunner-La Rocca HP, Hunziker P, Linka AZ, Osswald S, Buser PT, Pfisterer ME. Safety and efficacy of drug eluting stents versus bare metal stents in primary angioplasty of patients with acute ST-elevation myocardial infarction-a prospective randomized study. Eur Heart J 2006; 27: 650.

  11. Helsinki Area Acute Myocardial Infarction Treatment Re-Evaluation-Should the Patients Get a Drug-Eluting or Normal Stent (HAAMU-STENT) trial. wwwcardiosourcecom/pops/trialSumasp?trialID=1492 No publicado.

  12. A prospective randomized controlled trial to evaluate the efficacy of drug-eluting stents versus bare-metal stents for the treatment of acute myocardial infarction (MISSION trial). wwwcardiosourcecom/clinicaltrials/browseAcronymasp?alpha=M (No publicado)

  13. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JGP, Rensing BJ, Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 55: G1105-1113.

  14. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930.

  15. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293: 2109-2117.

  16. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C, for the TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 55: 1093-1104.

  17. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Emilio DL, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvänne M, Suttorp MJ, Violini R, Schömig A. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713.

  18. Hannan EL, Racz M, Walford G, Holmes DR, Jones RH, Sharma S, Katz S, King SB III. Drug-eluting versus bare-metal stents in the treatment of patients with st-segment elevation myocardial infarction. J Am Coll Cardiol Intv 2008; 1; 129-135.

  19. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, Ohman EM. Early reinfarction after fibrinolysis experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104; 1229-1235.

  20. Wenaweser P, Rey C, Eberli FR, Togni M, Tüller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. European Heart Journal 2005; 26: 1180-1187.

  21. Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ. Major bleeding complications in a specialized anticoagulation service. 2005; 96(4): 595-598.

  22. Doyle BJ, Ting HH, Bell MR, Lennon RJ, Verghese M, Mandeep S, Holmes DR, Rihal CS. Major femoral bleeding complications after percutaneous coronary intervention. J Am Coll Cardiol Intv 2008; 1; 202-209.

  23. Fischer U, Arnold M, Nedeltchev K, Brekenfeld C, Ballinari P, Remonda L, Schroth G, Mattle HP. Score and arteriographic findings in acute ischemic stroke. Stroke 2005; 36: 2121-2125.

  24. Sellier P, Plat F, Corona P, Payen B, Audouin P, Ourbak P. Prognostic significance of angina pectoris recurring soon after myocardial infarction. European Heart Journal 1988; 9: 447-453.

  25. Pitt B. Evaluation of the postinfarct patient. Circulation 1995; 91: 1855-1860.

  26. Laster SB, O’Keefe JH Jr, Gibbons RJ. Incidence and importance of thrombolysis in myocardial infarction grade 3 flow after primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 78: 623-626.

  27. Brodie BR, Grines CL, Ivanhoe R et al. Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. Circulation 1994; 90: 156-162.

  28. Cannon CP, Gibson CM, Lambrew CT et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283: 2941-2947.

  29. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13-20.

  30. Wilson SH, Bell MR, Rihal CS, Bailey KR, Holmes DR, Berger PB. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J 2001; 141: 704-710.

  31. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Jr, Alpert JS, Anderson JL, Faxon DP, Fuster VF, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2004; 110; e82-e293.

  32. Kastrati A; Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo M, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvänne M, Suttorp MJ, Violini RV, Schömig A. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713.

  33. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.

  34. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903.

  35. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-741.

  36. Montalescot G. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams? Eur Heart J 2004; 25: 1562-1564.

  37. Stellbrink C, Nixdorff U, Hofmann T et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997-1003.




2020     |     www.medigraphic.com